19 Min.

#35 - Samantha Dale Strasser, CEO & Co-Founder at Pepper Bio BioBreakthroughs

    • Wirtschaftsnachrichten

Join us on the latest episode! Our Guest: Samantha Dale Strasser, CEO & Co-Founder at Pepper Bio.
What you'll get out of this episode:
Samantha Dale Strasser, co-founder and Chief Science Officer of Pepper Bio, shares her transition from academia to entrepreneurship, driven by a personal mission to change healthcare outcomes.Pepper Bio, located in Boston, leverages transomics to integrate multiple data sets for precision medicine, aiming to treat diseases that are currently untreatable.Strasser’s focus is on developing treatments for challenging diseases, with an emphasis on oncology, inflammatory diseases, and neurodegenerative disorders.Pepper Bio’s approach in drug discovery combines its own pipeline development with strategic partnerships, speeding up the process of bringing new treatments to the clinic.The company has made significant strides in identifying novel targets and shelved assets, leading to a high success rate in in vivo model validations.
To learn more about our guests and their companies:LinkedIn: https://www.linkedin.com/in/samantha-dale-strasser/Company LinkedIn: https://www.linkedin.com/company/pepperbio/Website: https://pepper.bio/Our sponsor for this episode are:Sage Growth Partners https://sage-growth.com/
BioBreakthroughs is part of the Slice of Healthcare podcast network:LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

Join us on the latest episode! Our Guest: Samantha Dale Strasser, CEO & Co-Founder at Pepper Bio.
What you'll get out of this episode:
Samantha Dale Strasser, co-founder and Chief Science Officer of Pepper Bio, shares her transition from academia to entrepreneurship, driven by a personal mission to change healthcare outcomes.Pepper Bio, located in Boston, leverages transomics to integrate multiple data sets for precision medicine, aiming to treat diseases that are currently untreatable.Strasser’s focus is on developing treatments for challenging diseases, with an emphasis on oncology, inflammatory diseases, and neurodegenerative disorders.Pepper Bio’s approach in drug discovery combines its own pipeline development with strategic partnerships, speeding up the process of bringing new treatments to the clinic.The company has made significant strides in identifying novel targets and shelved assets, leading to a high success rate in in vivo model validations.
To learn more about our guests and their companies:LinkedIn: https://www.linkedin.com/in/samantha-dale-strasser/Company LinkedIn: https://www.linkedin.com/company/pepperbio/Website: https://pepper.bio/Our sponsor for this episode are:Sage Growth Partners https://sage-growth.com/
BioBreakthroughs is part of the Slice of Healthcare podcast network:LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/

19 Min.